parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (907 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 15860

MAP4K5 in dopamine neurons, braak+0.34 (p 0.374) → +0.11 (p 0.784)receipt 15868
MAP4K5 in oligodendrocytes, braak-0.25 (p 0.518) → +0.62 (p 0.078)receipt 15867

receipt 15868: MAP4K5 in dopamine neurons, braak

power: full sample +0.22 (p 0.374, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.332, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.319, n 18). could be the mix.
skeptic: leave-one-out range +0.13 to +0.37, sign flips 0; without severely affected donors +0.22 (p 0.374, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP4K5 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15867: MAP4K5 in oligodendrocytes, braak

power: full sample +0.14 (p 0.591, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.19 (p 0.444, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.28 (p 0.261, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.22, sign flips 0; without severely affected donors +0.14 (p 0.591, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP4K5 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts